A Phase 3 interventional study of Synflorix and Tritanrix-HepB in Infections, Streptococcal, sponsored by GlaxoSmithKline. Completed at 7 sites in 2 countries. Open to participants aged 12 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-14.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing PHiD-CV vaccine in Streptococcal Infections — none open to participants now, none under way, none of them phase 3. PHiD-CV vaccine · Streptococcal Infections.
Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, this one is the 5th largest by enrollment, is one of 4 that started in 2007, is one of 24 in phase 3, and was the 5th registered.
147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.
Browse Streptococcal Infections studies →None of the 25 studies testing PHiD-CV vaccine in Streptococcal Infections is open now. The open studies under Streptococcal Infections, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 12 Months to 18 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 756 is above the median of 270 across 106 interventional studies indexed under Streptococcal Infections.
Median enrollment 360 across the 25 interventional studies. Of the 25 that completed or were terminated, 25 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 25 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
64 studies in Streptococcal Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 61 finished, 44 (72%) have results posted.
Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, this one is the 14th largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2007, is one of 38 in phase 3, and was the 18th registered.
GlaxoSmithKline’s Streptococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 64 in Streptococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this observer blind study is to assess the safety in terms of fever >39°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK 1024850A at 12 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine and OPV or IPV vaccines. Subjects participating in this study should have received three doses of pneumococcal conjugate vaccine in the primary study.
This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00344318)
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
Biological: Synflorix · Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Polio Sabin
Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Polio Sabin · Biological: Prevenar (Wyeth)
Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
Biological: Synflorix · Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Poliorix
Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Poliorix · Biological: Prevenar (Wyeth)
Intramuscular injection, 1 dose
Also known as: Pneumococcal conjugate vaccine GSK1024850A
Drug page: Diphtheria-Tetanus-Pertussis Vaccine
Intramuscular injection, 1 dose
Also known as: DTPw-HBV vaccine
Reconstituted with Tritanrix-Hep B before injection
Also known as: Hib vaccine
Oral, 1 dose
Also known as: OPV
Intramuscular injection, 1 dose
Also known as: IPV
Intramuscular injection, 1 dose
Also known as: Pneumococcal conjugate vaccine
Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off
Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever \> 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.
Time frame: Within the 4-day (Days 0-3) period after booster vaccination
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Solicited local symptoms assessed included pain, redness and swelling. "Any" was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm).
Time frame: Within the 4-day (Days 0-3) period after booster vaccination
Number of Subjects With Any and Grade 3 Solicited General Symptoms
Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite."Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) \>40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.
Time frame: Within the 4-day (Days 0-3) period after booster vaccination
Number of Subjects With Unsolicited Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
Time frame: Within the 31-day (Days 0-30) period after booster vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
Time frame: Throughout the active phase of the study (Month 0 to Month 1)
Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off
The cut-off was 0.20 microgram per milliliter (μg/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations
Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Antibody Concentrations to Protein D (Anti-PD)
Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A
Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A
Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off
The cut-off of the assay was 0.05 μg/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off
The cut-off for the assay was 8.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off
The cut-of for the assay was 0.05 μg/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off
The cut-off for the assay was 8.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off
The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations
Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations
Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Anti-Bordetella Pertussis (BPT) Antibody Concentrations
Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations
Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Anti-polio Type 1, 2 and 3 Antibody Titers
Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off
The cut-off for the assay was 15 EL.U/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off
The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off
The cut-off for the assay was 0.15 μg/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off
The cut-off for the assay was 1.0 μg/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off
The cut-off for the assay was 10 mIU/mL.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off
The cut-off for the assay was 8.
Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)
Number of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)
Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.
Time frame: One month after booster vaccination (Month 1)
| Milestone | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Started | 280 | 93 | 285 | 98 |
| Completed | 280 | 93 | 275 | 96 |
| Not completed | 0 | 0 | 10 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Migrated/moved from study area | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 7 | 1 |
Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever \> 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.
| Participants | Synflorix Pooled Group | Prevenar Pooled Group |
|---|---|---|
| Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off | 64 | 20 |
Solicited local symptoms assessed included pain, redness and swelling. "Any" was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm).
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Any Pain | 203 | 66 | 248 | 77 |
| Grade 3 Pain | 40 | 20 | 117 | 39 |
| Any Redness | 107 | 37 | 197 | 66 |
| Grade 3 Redness | 8 | 3 | 35 | 11 |
| Any Swelling | 92 | 32 | 158 | 52 |
| Grade 3 Swelling | 21 | 9 | 34 | 8 |
Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite."Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) \>40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Any Drowsiness | 90 | 32 | 190 | 66 |
| Grade 3 Drowsiness | 5 | 1 | 7 | 2 |
| Any Fever | 138 | 51 | 215 | 65 |
| Grade 3 Fever | 0 | 0 | 1 | 0 |
| Any Irritability | 173 | 64 | 243 | 79 |
| Grade 3 Irritability | 12 | 3 | 40 | 5 |
| Any Loss of appetite | 97 | 28 | 184 | 57 |
| Grade 3 Loss of appetite | 8 | 1 | 13 | 1 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 25 | 9 | 106 | 35 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 2 | 0 | 5 | 2 |
The cut-off was 0.20 microgram per milliliter (μg/mL).
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-1, Month 0 | 100 | 2 | 64 | 2 |
| Anti-1, Month 1 | 136 | 3 | 125 | 2 |
| Anti-4, Month 0 | 113 | 25 | 78 | 23 |
| Anti-4, Month 1 | 136 | 43 | 125 | 43 |
| Anti-5, Month 0 | 118 | 7 | 98 | 3 |
| Anti-5, Month 1 | 136 | 8 | 124 | 3 |
| Anti-6B, Month 0 | 113 | 24 | 90 | 27 |
| Anti-6B, Month 1 | 134 | 42 | 122 | 41 |
| Anti-7F, Month 0 | 128 | 7 | 118 | 1 |
| Anti-7F, Month 1 | 136 | 9 | 125 | 1 |
| Anti-9V, Month 0 | 132 | 40 | 116 | 42 |
| Anti-9V, Month 1 | 136 | 43 | 125 | 43 |
| Anti-14, Month 0 | 126 | 42 | 111 | 40 |
| Anti-14, Month 1 | 135 | 43 | 125 | 43 |
| Anti-18C, Month 0 | 130 | 36 | 111 | 35 |
| Anti-18C, Month 1 | 136 | 43 | 125 | 43 |
| Anti-19F, Month 0 | 129 | 11 | 121 | 22 |
| Anti-19F, Month 1 | 136 | 43 | 123 | 43 |
| Anti-23F, Month 0 | 123 | 32 | 89 | 40 |
| Anti-23F, Month 1 | 135 | 42 | 123 | 42 |
Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
| μg/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-1, Month 0 | 0.35 (0.29 to 0.42) | 0.03 (0.03 to 0.04) | 0.19 (0.16 to 0.22) | 0.04 (0.03 to 0.05) |
| Anti-1, Month 1 | 10.8 (9.22 to 12.66) | 0.04 (0.03 to 0.05) | 2.14 (1.8 to 2.55) | 0.04 (0.03 to 0.05) |
| Anti-4, Month 0 | 0.55 (0.45 to 0.67) | 0.34 (0.25 to 0.45) | 0.27 (0.22 to 0.33) | 0.24 (0.19 to 0.3) |
| Anti-4, Month 1 | 13.16 (11.43 to 15.14) | 11.84 (8.74 to 16.04) | 4.21 (3.61 to 4.91) | 6.86 (5.39 to 8.73) |
| Anti-5, Month 0 | 0.55 (0.47 to 0.64) | 0.06 (0.04 to 0.09) | 0.4 (0.34 to 0.47) | 0.04 (0.03 to 0.05) |
| Anti-5, Month 1 | 14.59 (12.53 to 16.99) | 0.09 (0.06 to 0.13) | 2.54 (2.11 to 3.06) | 0.05 (0.04 to 0.06) |
| Anti-6B, Month 0 | 0.66 (0.54 to 0.8) | 0.38 (0.22 to 0.65) | 0.34 (0.28 to 0.41) | 0.34 (0.2 to 0.59) |
| Anti-6B, Month 1 | 7.02 (5.83 to 8.45) | 9.08 (6.5 to 12.7) | 2.31 (1.93 to 2.75) | 6.28 (4.18 to 9.44) |
| Anti-7F, Month 0 | 0.9 (0.77 to 1.04) | 0.05 (0.03 to 0.07) | 0.58 (0.51 to 0.67) | 0.03 (0.03 to 0.04) |
| Anti-7F, Month 1 | 12.52 (11.09 to 14.13) | 0.06 (0.04 to 0.1) | 4.14 (3.61 to 4.74) | 0.03 (0.03 to 0.04) |
| Anti-9V, Month 0 | 1.16 (0.98 to 1.37) | 0.77 (0.59 to 0.99) | 0.59 (0.5 to 0.7) | 0.58 (0.47 to 0.71) |
| Anti-9V, Month 1 | 14.42 (12.44 to 16.7) | 20.31 (15.44 to 26.71) | 4.63 (4 to 5.36) | 13.6 (11.12 to 16.62) |
| Anti-14, Month 0 | 1.32 (1.07 to 1.63) | 1.83 (1.26 to 2.66) | 0.84 (0.66 to 1.07) | 1.04 (0.75 to 1.43) |
| Anti-14, Month 1 | 17.07 (14.12 to 20.64) | 27.42 (20.96 to 35.86) | 5.93 (4.97 to 7.09) | 15.51 (12.14 to 19.82) |
| Anti-18C, Month 0 | 1.43 (1.2 to 1.71) | 0.42 (0.32 to 0.55) | 0.63 (0.52 to 0.77) | 0.4 (0.3 to 053) |
| Anti-18C, Month 1 | 39.59 (34.04 to 46.05) | 12.07 (9.23 to 15.79) | 10.49 (8.81 to 12.49) | 9.92 (7.74 to 12.71) |
| Anti-19F, Month 0 | 1.33 (1.08 to 1.64) | 0.16 (0.1 to 0.26) | 0.99 (0.81 to 1.22) | 0.35 (0.2 to 0.61) |
| Anti-19F, Month 1 | 21.25 (18.07 to 24.98) | 6.61 (4.9 to 8.92) | 12.23 (9.89 to 15.13) | 6.01 (4.75 to 7.6) |
| Anti-23F, Month 0 | 0.94 (0.76 to 1.16) | 0.41 (0.26 to 0.64) | 0.33 (0.27 to 0.4) | 0.62 (0.43 to 0.91) |
| Anti-23F, Month 1 | 13.47 (11.38 to 15.94) | 14.78 (9.45 to 23.11) | 3.16 (2.61 to 3.83) | 10.77 (7.19 to 16.12) |
Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.
| Titers | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| OPA Anti-1, Month 0 | 13.2 (10.2 to 16.9) | 4.6 (3.9 to 5.4) | 8.5 (7 to 10.5) | 4.7 (3.8 to 5.8) |
| OPA Anti-1, Month 1 | 1571.6 (1210.7 to 2040) | 4.9 (4.1 to 5.8) | 161.4 (120.7 to 215.9) | 5.4 (4 to 7.4) |
| OPA Anti-4, Month 0 | 40.5 (27.6 to 59.2) | 18.5 (10 to 34.2) | 12.5 (8.9 to 17.4) | 12.4 (6.7 to 22.8) |
| OPA Anti-4, Month 1 | 5035.8 (4214 to 6017.8) | 4783.5 (3432 to 6667.2) | 2498.7 (2103.3 to 2968.4) | 4812.5 (3167.8 to 7311.3) |
| OPA Anti-5, Month 0 | 19.8 (16 to 24.7) | 4.2 (3.8 to 4.6) | 10.9 (8.8 to 13.6) | 4.5 (3.7 to 5.5) |
| OPA Anti-5, Month 1 | 1135.8 (928.5 to 1389.6) | 4.9 (3.9 to 6) | 149.1 (115.4 to 192.5) | 4.3 (3.8 to 4.8) |
| OPA Anti-6B, Month 0 | 97.8 (61.5 to 155.5) | 56.6 (21.3 to 150.1) | 9.9 (7.2 to 13.5) | 23.3 (9.1 to 60.1) |
| OPA Anti-6B, Month 1 | 2896.8 (2247.5 to 3733.8) | 9302.7 (7187.3 to 12040.8) | 405.3 (267.4 to 614.3) | 3547.1 (1500.7 to 8384.5) |
| OPA Anti-7F, Month 0 | 2278.4 (1803.1 to 2879) | 378.8 (136.9 to 1048) | 796.3 (582.2 to 1089.1) | 63.6 (21.3 to 190.1) |
| OPA Anti-7F, Month 1 | 12484 (10750.7 to 14496.8) | 1407.7 (694.6 to 2852.9) | 6436.1 (5507.6 to 7521) | 90.6 (25.2 to 325.5) |
| OPA Anti-9V, Month 0 | 788 (655.1 to 947.8) | 666.8 (482.1 to 922.2) | 380.2 (313.1 to 461.7) | 247.5 (164.9 to 371.3) |
| OPA Anti-9V, Month 1 | 4842 (4122.7 to 5686.9) | 7387.8 (5429.2 to 10052.9) | 3499.9 (2950.8 to 4151.3) | 6881.4 (4883.6 to 9696.4) |
| OPA Anti-14, Month 0 | 298.4 (220.1 to 404.7) | 337.2 (207 to 549.2) | 179.6 (127.4 to 253.2) | 236.6 (132.6 to 422.2) |
| OPA Anti-14, Month 1 | 3579.7 (2966.3 to 4319.9) | 4097.3 (3019.2 to 5560.2) | 1961.3 (1630 to 2359.8) | 2939.5 (2022.3 to 4272.7) |
| OPA Anti-18C, Month 0 | 19.8 (15.2 to 25.9) | 4.5 (3.9 to 5.2) | 7.8 (6.5 to 9.4) | 4.5 (4 to 5.2) |
| OPA Anti-18C, Month 1 | 2417.2 (1989.9 to 2936.2) | 966.5 (607.1 to 1538.6) | 694 (532.9 to 903.7) | 612.1 (338.4 to 1107) |
| OPA Anti-19F, Month 0 | 58.6 (45.2 to 76) | 7.3 (4.5 to 11.8) | 33.3 (25.7 to 43.2) | 11.1 (6 to 20.6) |
| OPA Anti-19F, Month 1 | 2016 (1609 to 2526) | 473.2 (263.5 to 849.9) | 1059.8 (808.2 to 1389.7) | 471 (270 to 821.8) |
| OPA Anti-23F, Month 0 | 948.9 (688.4 to 1308.2) | 661.9 (312.5 to 1402) | 301.8 (198.4 to 459) | 790.6 (326.8 to 1912.6) |
| OPA Anti-23F, Month 1 | 7456.2 (6301.9 to 8822) | 23177.9 (13235.9 to 40587.7) | 3427.3 (2727.7 to 4306.3) | 19943.3 (13473.1 to 29520.5) |
Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-PD, Month 0 | 573.1 (495.7 to 662.6) | 136.8 (102 to 183.3) | 526.8 (427.4 to 649.3) | 73.8 (58.4 to 93.2) |
| Anti-PD, Month 1 | 4973.9 (4280.2 to 5780) | 124.1 (92.8 to 166) | 2769.6 (2308.5 to 3322.7) | 91.6 (72 to 116.7) |
Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
| μg/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-6A, Month 0 | 0.46 (0.36 to 0.6) | 0.24 (0.14 to 0.4) | 0.12 (0.1 to 0.14) | 0.13 (0.08 to 0.2) |
| Anti-6A, Month 1 | 4.07 (3.09 to 5.36) | 4.57 (2.92 to 7.17) | 0.84 (0.65 to 1.08) | 2.54 (1.65 to 3.93) |
| Anti-19A, Month 0 | 0.24 (0.19 to 0.3) | 0.08 (0.05 to 0.12) | 0.16 (0.12 to 0.2) | 0.06 (0.04 to 0.08) |
| Anti-19A, Month 1 | 3.22 (2.46 to 4.21) | 0.58 (0.37 to 0.91) | 1.75 (1.27 to 2.43) | 0.38 (0.25 to 0.58) |
Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.
| Titers | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| OPA Anti-6A, Month 0 | 113.6 (73.6 to 175.4) | 191.4 (89.7 to 408.2) | 46.8 (30.8 to 71.1) | 42.2 (19.3 to 92.1) |
| OPA Anti-6A, Month 1 | 882.8 (665.9 to 1170.3) | 2563.8 (1689.9 to 3889.4) | 369.7 (258.5 to 528.8) | 1394.5 (827.9 to 2348.9) |
| OPA Anti-19A, Month 0 | 5.3 (4.5 to 6.3) | 5.1 (3.6 to 7.3) | 5.3 (4.5 to 6.2) | 4.4 (3.6 to 5.3) |
| OPA Anti-19A, Month 1 | 89.3 (58.9 to 135.4) | 8.7 (5.4 to 14.2) | 70.7 (45.3 to 110.4) | 20.3 (8.8 to 46.8) |
The cut-off of the assay was 0.05 μg/mL.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-1, Month 0 | 135 | 7 | 122 | 8 |
| Anti-1, Month 1 | 136 | 11 | 125 | 9 |
| Anti-4, Month 0 | 134 | 43 | 126 | 42 |
| Anti-4, Month 1 | 136 | 43 | 125 | 43 |
| Anti-5, Month 0 | 135 | 18 | 128 | 13 |
| Anti-5, Month 1 | 136 | 31 | 125 | 20 |
| Anti-6B, Month 0 | 132 | 40 | 127 | 39 |
| Anti-6B, Month 1 | 135 | 42 | 124 | 42 |
| Anti-7F, Month 0 | 135 | 13 | 130 | 8 |
| Anti-7F, Month 1 | 136 | 17 | 125 | 11 |
| Anti-9V, Month 0 | 135 | 42 | 130 | 44 |
| Anti-9V, Month 1 | 136 | 43 | 125 | 43 |
| Anti-14, Month 0 | 134 | 42 | 130 | 43 |
| Anti-14, Month 1 | 136 | 43 | 125 | 43 |
| Anti-18C, Month 0 | 135 | 43 | 129 | 44 |
| Anti-18C, Month 1 | 136 | 43 | 125 | 43 |
| Anti-19F, Month 0 | 134 | 37 | 129 | 43 |
| Anti-19F, Month 1 | 136 | 43 | 124 | 43 |
| Anti-23F, Month 0 | 132 | 40 | 125 | 43 |
| Anti-23F, Month 1 | 136 | 42 | 124 | 42 |
The cut-off for the assay was 8.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| OPA Anti-1, Month 0 | 61 | 3 | 45 | 3 |
| OPA Anti-1, Month 1 | 134 | 5 | 114 | 5 |
| OPA Anti-4, Month 0 | 83 | 20 | 39 | 12 |
| OPA Anti-4, Month 1 | 134 | 43 | 119 | 35 |
| OPA Anti-5, Month 0 | 94 | 1 | 56 | 2 |
| OPA Anti-5, Month 1 | 130 | 4 | 114 | 1 |
| OPA Anti-6B, Month 0 | 93 | 21 | 34 | 14 |
| OPA Anti-6B, Month 1 | 134 | 43 | 106 | 32 |
| OPA Anti-7F, Month 0 | 133 | 28 | 109 | 15 |
| OPA Anti-7F, Month 1 | 136 | 36 | 122 | 13 |
| OPA Anti-9V, Month 0 | 135 | 42 | 121 | 36 |
| OPA Anti-9V, Month 1 | 134 | 42 | 121 | 35 |
| OPA Anti-14, Month 0 | 119 | 39 | 93 | 29 |
| OPA Anti-14, Month 1 | 132 | 42 | 120 | 36 |
| OPA Anti-18C, Month 0 | 84 | 3 | 42 | 4 |
| OPA Anti-18C, Month 1 | 133 | 42 | 114 | 36 |
| OPA Anti-19F, Month 0 | 117 | 7 | 96 | 12 |
| OPA Anti-19F, Month 1 | 135 | 39 | 118 | 36 |
| OPA Anti-23F, Month 0 | 130 | 37 | 99 | 30 |
| OPA Anti-23F, Month 1 | 136 | 42 | 120 | 37 |
The cut-of for the assay was 0.05 μg/mL.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-6A, Month 0 | 128 | 37 | 105 | 33 |
| Anti-6A, Month 1 | 133 | 42 | 125 | 42 |
| Anti-19A, Month 0 | 124 | 25 | 105 | 27 |
| Anti-19A, Month 1 | 135 | 42 | 119 | 42 |
The cut-off for the assay was 8.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| OPA Anti-6A, Month 0 | 82 | 30 | 63 | 19 |
| OPA Anti-6A, Month 1 | 127 | 43 | 97 | 32 |
| OPA Anti-19A, Month 0 | 14 | 2 | 11 | 1 |
| OPA Anti-19A, Month 1 | 92 | 11 | 74 | 12 |
The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-PD, Month 0 | 131 | 28 | 117 | 11 |
| Anti-PD, Month 1 | 135 | 23 | 125 | 19 |
Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
| IU/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-DT, Month 0 | 0.258 (0.209 to 0.319) | 0.17 (0.118 to 0.243) | 0.188 (0.153 to 0.231) | 0.126 (0.088 to 0.179) |
| Anti-DT, Month 1 | 7.829 (6.339 to 9.671) | 4.768 (3.699 to 6.145) | 8.463 (7.11 to 10.074) | 4.876 (3.503 to 6.787) |
| Anti-TT, Month 0 | 0.735 (0.629 to 0.858) | 0.455 (0.314 to 0.66) | 0.568 (0.432 to 0.748) | 0.525 (0.29 to 0.951) |
| Anti-TT, Month 1 | 20.979 (18.359 to 23.972) | 9.703 (8.173 to 11.518) | 12.171 (9.772 to 15.16) | 6.719 (4.598 to 9.819) |
Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.
| μg/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix™ Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-PRP, Month 0 | 5.335 (3.578 to 7.953) | 6.433 (2.93 to 14.124) | 1.03 (0.745 to 1.423) | 0.894 (0.57 to 1.401) |
| Anti-PRP, Month 1 | 106.004 (79.937 to 140.572) | 89.376 (55.131 to 144.891) | 53.386 (34.817 to 81.858) | 33.656 (19.464 to 58.198) |
Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.
| EL.U/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-BPT, Month 0 | 12.88 (10.86 to 15.28) | 12.46 (9.32 to 16.65) | 9.54 (8.34 to 10.91) | 10 (8.21 to 12.19) |
| Anti-BPT, Month 1 | 139.51 (123.26 to 157.89) | 133.45 (110.33 to 161.4) | 121.73 (103.16 to 143.64) | 121.76 (91.81 to 161.47) |
Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).
| mIU/mL | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-HBs, Month 0 | 30 (21.1 to 42.8) | 23.4 (11.5 to 47.7) | 97.9 (77 to 124.5) | 113 (55.1 to 231.7) |
| Anti-HBs, Month 1 | 1220.5 (790.6 to 1884) | 1098.1 (358.4 to 3364.9) | 4428.7 (2980.3 to 6581) | 3188.6 (1171.7 to 8677.1) |
Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.
| Titers | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix™ Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-Polio 1, Month 0 | 329.1 (214.9 to 504.1) | 269 (114.8 to 630.3) | 46.5 (33.6 to 64.4) | 51.1 (28.4 to 91.9) |
| Anti-Polio 1, Month 1 | 854.6 (573.5 to 1273.5) | 426.9 (166.2 to 1096.7) | 932.5 (770.5 to 1128.6) | 727.3 (512.9 to 1059.9) |
| Anti-Polio 2, Month 0 | 222.6 (171.8 to 288.3) | 210.4 (115.4 to 383.6) | 50.2 (36.9 to 68.2) | 60.8 (33.4 to 110.8) |
| Anti-Polio 2, Month 1 | 716.9 (487.6 to 1054.1) | 689.1 (304.8 to 1557.9) | 1195.7 (977.8 to 1462.2) | 1206.6 (737 to 1975.4) |
| Anti-Polio 3, Month 0 | 102.2 (73.9 to 141.5) | 38.4 (20.3 to 72.9) | 51.8 (37.4 to 71.7) | 71.1 (36.2 to 139.5) |
| Anti-Polio 3, Month 1 | 232.7 (159.6 to 339.4) | 190.4 (78.2 to 463.6) | 1464.2 (1128 to 1900.6) | 1346.2 (857.6 to 2113.2) |
The cut-off for the assay was 15 EL.U/mL.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-BPT, Month 0 | 28 | 10 | 12 | 7 |
| Anti-BPT, Month 1 | 65 | 25 | 59 | 24 |
The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-DT, Month 0 | 56 | 18 | 49 | 15 |
| Anti-DT, Month 1 | 65 | 25 | 59 | 24 |
| Anti-TT, Month 0 | 65 | 24 | 60 | 23 |
| Anti-TT, Month 1 | 65 | 25 | 58 | 24 |
The cut-off for the assay was 0.15 μg/mL.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-PRP, Month 0 | 65 | 25 | 58 | 23 |
| Anti-PRP, Month 1 | 65 | 25 | 59 | 24 |
The cut-off for the assay was 1.0 μg/mL.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-PRP, Month 0 | 56 | 22 | 32 | 12 |
| Anti-PRP, Month 1 | 65 | 25 | 57 | 24 |
The cut-off for the assay was 10 mIU/mL.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-HBs, Month 0 | 53 | 13 | 63 | 19 |
| Anti-HBs, Month 1 | 68 | 19 | 62 | 19 |
The cut-off for the assay was 8.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-Polio 1, Month 0 | 64 | 19 | 56 | 19 |
| Anti-Polio 1, Month 1 | 68 | 19 | 63 | 19 |
| Anti-Polio 2, Month 0 | 69 | 21 | 59 | 19 |
| Anti-Polio 2, Month 1 | 69 | 21 | 63 | 19 |
| Anti-Polio 3, Month 0 | 65 | 17 | 61 | 18 |
| Anti-Polio 3, Month 1 | 66 | 20 | 63 | 19 |
Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.
| Participants | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| Anti-BPT, S- | 37 | 15 | 48 | 16 |
| Anti-BPT, S+ | 27 | 8 | 11 | 7 |
Collected over Solicited local and general symptoms during the 4-day and unsolicited AEs during the 31- day after booster vaccination; serious adverse events (SAEs): throughout the entire study period from Month 0 to Month 6. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | 0/280 (0%) | 6/280 (2.1%) | 237/280 (84.6%) |
| Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | 1/93 (1.1%) | 1/93 (1.1%) | 78/93 (83.9%) |
| Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | 0/285 (0%) | 14/285 (4.9%) | 276/285 (96.8%) |
| Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group | 0/98 (0%) | 5/98 (5.1%) | 92/98 (93.9%) |
| Event | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/280 | 0/93 | 5/285 | 2/98 |
| Internal injuryInjury, poisoning and procedural complications | 0/280 | 1/93 | 0/285 | 0/98 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/280 | 1/93 | 0/285 | 0/98 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/280 | 1/93 | 0/285 | 0/98 |
| Febrile convulsionNervous system disorders | 3/280 | 0/93 | 1/285 | 0/98 |
| PneumoniaInfections and infestations | 1/280 | 0/93 | 3/285 | 1/98 |
| PharyngitisInfections and infestations | 0/280 | 0/93 | 3/285 | 0/98 |
| AnaemiaBlood and lymphatic system disorders | 0/280 | 0/93 | 0/285 | 1/98 |
| HypoglobulinaemiaBlood and lymphatic system disorders | 0/280 | 0/93 | 0/285 | 1/98 |
| LymphadenitisBlood and lymphatic system disorders | 0/280 | 0/93 | 0/285 | 1/98 |
| Event | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group |
|---|---|---|---|---|
| PainGeneral disorders | 203/280 | 66/93 | 248/285 | 77/98 |
| IrritabilityPsychiatric disorders | 173/280 | 64/93 | 244/285 | 79/98 |
| PyrexiaGeneral disorders | 138/280 | 51/93 | 215/285 | 65/98 |
| ErythemaSkin and subcutaneous tissue disorders | 107/280 | 37/93 | 197/285 | 66/98 |
| SomnolenceNervous system disorders | 90/280 | 32/93 | 190/285 | 66/98 |
| Decreased appetiteMetabolism and nutrition disorders | 97/280 | 28/93 | 184/285 | 57/98 |
| SwellingGeneral disorders | 92/280 | 32/93 | 158/285 | 52/98 |
| PharyngitisInfections and infestations | 0/280 | 0/93 | 4/285 | 6/98 |
| NasopharyngitisInfections and infestations | 0/280 | 0/93 | 14/285 | 5/98 |
| RhinitisInfections and infestations | 3/280 | 2/93 | 11/285 | 5/98 |
| Age, Continuous(Months) | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix - HepB/ Hiberix + Poliorix Group | Total |
|---|---|---|---|---|---|
| Geometric mean | 16.2 ± 0.66 | 16.2 ± 0.59 | 17.2 ± 0.84 | 17.2 ± 0.88 | 16.71 ± 0.90 |
| Sex/Gender, Customized(Participants) | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix - HepB/ Hiberix + Poliorix Group | Total |
|---|---|---|---|---|---|
| Gender Categorical — Female | 133 | 43 | 134 | 43 | 353 |
| Gender Categorical — Male | 147 | 50 | 151 | 55 | 403 |
| Race/Ethnicity, Customized(Participants) | Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group | Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group | Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group | Prevenar + Tritanrix - HepB/ Hiberix + Poliorix Group | Total |
|---|---|---|---|---|---|
| Geographic ancestry — White - Caucasian / European heritage | 0 | 0 | 285 | 98 | 383 |
| Geographic ancestry — Asian - south east Asian heritage | 280 | 93 | 0 | 0 | 373 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Oct 2007 to primary completion in May 2008, 6 months.
Results were first posted in Jan 2019, 10 years 8 months after primary completion. A results delay was requested in May 2009.
Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 6 months is below that.
Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PHiD-CV vaccine · Poliovirus Vaccine, Oral · Poliovirus Vaccine, Inactivated